Panmure Liberum says OxfordBiomedica share fall overdone after Novartis and BMS pause trials
Panmure Liberum has maintained its buy rating on Oxford BioMedica PLC (LSE:OXB), the cell and gene therapy manufacturer, after its…
£4,450
-5,52%
Echtzeit-Aktienkurs Oxford Biomedica PLC
Bid:
Ask:
Nachrichten zur Oxford Biomedica PLC Aktie
Panmure Liberum says OxfordBiomedica share fall overdone after Novartis and BMS pause trials
Panmure Liberum has maintained its buy rating on Oxford BioMedica PLC (LSE:OXB), the cell and gene therapy manufacturer, after its…
FTSE 100 Live: FTSE 100 recovers some ground as Wall Street heads lower
FTSE 100 down 44 points at 10,780 Manufacturing PMI slips to 51.7 Factory hiring grows at fastest rate in over two years…
Oxford Biomedica plc (OXBDF) Analyst/Investor Day - Slideshow
…
Oxford BioMedica reiterates FY2026 guidance
Oxford BioMedica reiterates FY2026 guidance…
Oxford BioMedica reports strong H1 with revenue up 38-44% By Investing.com
Oxford BioMedica reports strong H1 with revenue up 38-44%…
Oxford Biomedica plc (OXBDF) Q4 2024 Earnings Call Transcript
…
Oxford Biomedica plc (OXBDF) Q2 2024 Earnings Call Transcript
…
Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today
Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today…
Oxford Biomedica announces CFO transition
Oxford Biomedica announces Chief Financial Officer transition…
Oxford Biomedica plc (OXBDF) Q4 2023 Earnings Call Transcript
…